Luigi Rigacci

9.6k total citations · 2 hit papers
144 papers, 4.0k citations indexed

About

Luigi Rigacci is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Luigi Rigacci has authored 144 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Pathology and Forensic Medicine, 56 papers in Genetics and 50 papers in Oncology. Recurrent topics in Luigi Rigacci's work include Lymphoma Diagnosis and Treatment (103 papers), Chronic Lymphocytic Leukemia Research (50 papers) and CNS Lymphoma Diagnosis and Treatment (27 papers). Luigi Rigacci is often cited by papers focused on Lymphoma Diagnosis and Treatment (103 papers), Chronic Lymphocytic Leukemia Research (50 papers) and CNS Lymphoma Diagnosis and Treatment (27 papers). Luigi Rigacci collaborates with scholars based in Italy, United States and Ukraine. Luigi Rigacci's co-authors include Umberto Vitolo, Francesco Merli, Stefano Luminari, Caterina Stelitano, Alberto Bosi, Francesco Di Raimondo, Alessandro Levis, Andrea Gallamini, Emilio Iannitto and Benedetta Puccini and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Luigi Rigacci

137 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Early Interim 2-[ ¹⁸ F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study

2007 552 citations Andrea Gallamini, Martin Hutchings et al. Journal of Clinical Oncology profile →
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project

2009 506 citations Stefano Luminari, Armando López‐Guillermo et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Luigi Rigacci

Since Specialization

Citations

This map shows the geographic impact of Luigi Rigacci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luigi Rigacci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luigi Rigacci more than expected).

Fields of papers citing papers by Luigi Rigacci

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luigi Rigacci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luigi Rigacci. The network helps show where Luigi Rigacci may publish in the future.

Co-authorship network of co-authors of Luigi Rigacci

This figure shows the co-authorship network connecting the top 25 collaborators of Luigi Rigacci. A scholar is included among the top collaborators of Luigi Rigacci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luigi Rigacci. Luigi Rigacci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus 2025 ·Cytotherapy ·Stefano Luminari, Annalisa Chiappella, Alice Di Rocco, Luca Arcaini, Roberto Freilone, (unknown), Massimo Martino, Pellegrino Musto, Luigi Rigacci, (unknown), Paolo Corradini, Pier Luigi Zinzani	0
2	A SWOT‐Consensus for CAR‐T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection 2025 ·Hematological Oncology ·Monia Marchetti, Paolo Corradini, Luca Arcaini, Stéfania Bramanti, Alice Di Rocco, Marco Ladetto, Stefano Luminari, Luigi Rigacci, Pier Luigi Zinzani	0
3	Stem Cells Collection and Mobilization in Adult Autologous/Allogeneic Transplantation: Critical Points and Future Challenges 2024 ·Cells ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ombretta Annibali, Luigi Rigacci, (unknown)	3
4	Neuroradiology of acute pathologies in adults with hematologic malignancies: a pictorial review 2023 ·Quantitative Imaging in Medicine and Surgery ·Carlo Augusto Mallio, (unknown), (unknown), (unknown), (unknown), Ombretta Annibali, Luigi Rigacci, Johan Van Goethem, Paul M. Parizel, Bruno Beomonte Zobel, Carlo Cosimo Quattrocchi	1
5	Effects of ABVD chemotherapy on ovarian function: epidemiology, hormonal dosages and ultrasound morphologic analyses in 270 patients with Hodgkin’s disease 2023 ·Frontiers in Oncology ·(unknown), (unknown), (unknown), (unknown), Alessandro Pulsoni, Ombretta Annibali, (unknown), Roberta Battistini, Stefan Hohaus, (unknown), Agostino Tafuri, (unknown), Maria Cantonetti, Luigi Rigacci, Elisabetta Abruzzese	4
6	Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience 2022 ·Cancers ·Matteo Molica, Carla Mazzone, Pasquale Niscola, Ida Carmosino, Ambra Di Veroli, (unknown), F Bonanni, Salvatore Perrone, (unknown), Luana Fianchi, Anna Lina Piccioni, Antonio Spadea, (unknown), Andrea Mengarelli, Laura Cudillo, Luca Maurillo, Livio Pagano, Massimo Breccia, Luigi Rigacci, Paolo de Fabritiis	6
7	A Gene Expression–based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients 2019 ·Clinical Cancer Research ·Stefano Luminari, Benedetta Donati, Massimiliano Casali, Riccardo Valli, Raffaella Santi, Benedetta Puccini, Sofya Kovalchuk, (unknown), Angelo Famà, Valentina Berti, Valentina Fragliasso, Magda Zanelli, Federica Vergoni, Annibale Versari, Luigi Rigacci, Francesco Merli, Alessia Ciarrocchi	11
8	Prognostic models for primary mediastinal (thymic) B‐cell lymphoma derived from 18‐FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study 2017 ·British Journal of Haematology ·Luca Ceriani, Maurizio Martelli, Annarita Conconi, Pier Luigi Zinzani, Andrés J.M. Ferreri, Barbara Botto, Caterina Stelitano, Manuel Gotti, Maria Giuseppina Cabras, Luigi Rigacci, Luca Giovanella, Emanuele Zucca, Peter Johnson	23
9	Safety and Activity of a Dose-Dense Short-Term Chemoimmunotherapy in HIV-Positive Patients with Burkitt Lymphoma (HIV-BL pts): Final Results of the Carmen Phase II Trial 2017 ·Blood ·Andrés J.M. Ferreri, Michele Spina, Chiara Cattaneo, Luisa Verga, Bernardino Allione, Daris Ferrari, Luigi Rigacci, Luca Fumagalli, Giovanni Donadoni, Arben Lleshi, Marianna Sassone, Giuseppe Rossi, Alessandro Re	1
10	Comparison of Long-Term Outcome in Anthracycline-Related Versus Idiopathic Dilated Cardiomyopathy: A Single Centre Experience 2017 ·European Journal of Heart Failure ·Alessandra Fornaro, Iacopo Olivotto, Luigi Rigacci, M Ciaccheri, Benedetta Tomberli, Cecilia Ferrantini, Raffaele Coppini, Francesca Girolami, Francesco Mazzarotto, Marco Chiostri, Massimo Milli, Niccolò Marchionni, Gabriele Castelli	44
11	[ ¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study 2014 ·Journal of Clinical Oncology ·Maurizio Martelli, Luca Ceriani, Emanuele Zucca, Pier Luigi Zinzani, Andrés J.M. Ferreri, Umberto Vitolo, Caterina Stelitano, Ercole Brusamolino, Maria Giuseppina Cabras, Luigi Rigacci, Monica Balzarotti, Flavia Salvi, Silvia Montoto, Armando López‐Guillermo, Erica Finolezzi, Stefano Pileri, Andrew Davies, Franco Cavalli, Luca Giovanella, Peter Johnson	106
12	R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL) 2012 ·American Journal of Clinical Oncology ·Massimo Federico, Stefano Luminari, Alessandra Dondi, Stefano Sacchi, (unknown), S Pileri, Marco Lombardo, Giuseppe Rossi, Luca Arcaini, Teodoro Chisesi, Mario Petrini, Sara Galimberti, Umberto Vitolo, Francesco Di Raimondo, Luigi Rigacci, Carella Am, F. Angrilli, Roberto Freilone, Andrés J.M. Ferreri, (unknown)	6
13	Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients 2011 ·European Journal of Nuclear Medicine and Molecular Imaging ·Pier Luigi Zinzani, Luigi Rigacci, Vittorio Stefoni, Alessandro Broccoli, Benedetta Puccini, Antonio Castagnoli, Luca Vaggelli, Lucia Zanoni, Lisa Argnani, Michele Baccarani, Stefano Fanti	82
14	Rituximab and Subcutaneous 2-Chloro-2′-Deoxyadenosine Combination Treatment for Patients With Waldenström Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter Study 2010 ·Journal of Clinical Oncology ·Daniele Laszlò, Giovanna Andreola, Luigi Rigacci, Alberto Fabbri, Cristina Rabascio, Patrizia Mancuso, Giancarlo Pruneri, Davide Radice, Antonio Pinto, Ferdinando Frigeri, Liliana Calabrese, Atto Billio, Francesco Bertolini, Giovanni Martinelli	41
15	Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG) 2010 ·Annals of Oncology ·Annarita Conconi, Giovanni Martinelli, Armando López‐Guillermo, Pier Luigi Zinzani, Andrés J.M. Ferreri, Luigi Rigacci, Liliana Devizzi, Umberto Vitolo, Stefano Luminari, Franco Cavalli, Emanuele Zucca	54
16	Early Interim 2-[ ¹⁸ F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study breakdown → 2007 ·Journal of Clinical Oncology ·Andrea Gallamini, Martin Hutchings, Luigi Rigacci, Lena Specht, Francesco Merli, Mads Hansen, Caterina Patti, Annika Loft, Francesco Di Raimondo, Francesco d’Amore, Alberto Biggi, Umberto Vitolo, Caterina Stelitano, (unknown), Livio Trentin, Stefano Luminari, Emilio Iannitto, Simonetta Viviani, Ivana Pierri, Alessandro Levis	552
17	[630] CAN DEPLETION OF B-CELLS BY ANTI-CD20 MONOCLONAL ANTIBODY IN HCV+ MIXED CRYOGLOBULINEMIA (MC) IMPROVE LIVER CIRRHOSIS? 2007 ·Journal of Hepatology ·A. Petrarca, Luigi Rigacci, C. Giannini, Roberto Caporale, Paolo Montalto, Alberto Bosi, Giacomo Laffi, Anna Linda Zignego	1
18	CHOP Chemotherapy Plus Campath-1H (CHOP-C) as First Line Treatment in Patients with Peripheral T-Cell Lymphoma (PTCL). 2005 ·Blood ·Andrea Gallamini, Francesco Zaja, Livio Gargantini, Annunziata Manna, (unknown), Alessandro Levis, Luigi Rigacci, Patrizio Mazza, Emilio Iannitto, Antonio Pinto, Alessandra Tucci, Caterina Patti, Valerio Zoli, Alessandro Federico	7
19	PET Scan Evaluation of Thymic Mass After Autologous Peripheral Blood Stem-cell Transplantation in an Adult with Non-Hodgkin's Lymphoma 2003 ·Leukemia & lymphoma ·F. Pagliai, Luigi Rigacci, Vittorio Briganti, (unknown), Antonio Castagnoli, Luca Vaggelli, Alberto Bosi	9
20	A new protocol (MiCEP) for the treatment of intermediate or high-grade non-hodgkin's lymphoma in the elderly 1996 ·Leukemia & lymphoma ·(unknown), Luigi Rigacci, Renato Alterini, (unknown), (unknown), (unknown), (unknown), Giovanni Longo, Simonetta Di Lollo, (unknown)	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact